Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

DUBLIN--(BUSINESS WIRE)--The "Mexico Life Insurance: Key Trends and Opportunities to 2029" report has been added to ResearchAndMarkets.com's offering. The report provides in-depth market analysis, information, and insights into Mexico's life insurance segment. It provides values for key performance indicators such as gross written premium, penetration, and premium ceded and cession rates during the review period (2020-24) and forecast period (2025-29). The report also analyzes distribution chan...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetic...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 08.12.2025 FVD. IE00BKVKW020 250,002.00 USD 6,907,102.55 27.628  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 08.12.2025 FCSG IE00BKPSPT20 1,500,002.00 USD 63,936,296.76 42.624  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 08.12.2025 FXGB LN IE00BD5HBR05 37,992.00 GBP 737,293.43 25.835  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 08.12.2025 FTFX IE00BD5HBQ97 63,402.00 USD 1,627,196.25 25.665  ...

MONTREAL--(BUSINESS WIRE)--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO). Dr. Maki brings over 20 years of biopharmaceutical industry experience, including leadership roles in business development, licensing, and corporate venture across both emerging biotech ventures and global pharmaceutical companies. Her background includes seni...

MONTRÉAL--(BUSINESS WIRE)--Ability Biotherapeutics, une compagnie de biothérapeutiques qui développe des thérapies à base d’anticorps à activation logique pour le traitement du cancer et des maladies auto-immunes, annonce la nomination d’Angèle Maki, Ph. D., au poste de Cheffe de la direction commerciale (Chief Business Officer – CBO). La Dre Maki cumule plus de 20 ans d’expérience dans l’industrie biopharmaceutique, ayant notamment occupé des rôles de direction en développement des affaires, e...